The global microRNA market size is calculated at USD 2.16 billion in 2025 and is predicted to surpass around USD 10.18 billion by 2034, accelerating at a CAGR of 18.92% from 2025 to 2034. The North America microRNA market size surpassed USD 860 million in 2024 and is expanding at a CAGR of 18.96% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: MicroRNA Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. MicroRNA Market Revenue and Volume Forecast, by Products
8.1.1. Instruments
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Consumables
8.1.2.1. Market Revenue and Volume Forecast
9.1. MicroRNA Market Revenue and Volume Forecast, by Services
9.1.1. Service Type
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Specimen
9.1.2.1. Market Revenue and Volume Forecast
10.1. MicroRNA Market Revenue and Volume Forecast, by Application
10.1.1. Cancer
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Immunological Disorder
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Cardiovascular Disease
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Neurological Disease
10.1.5.1. Market Revenue and Volume Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Volume Forecast
11.1. MicroRNA Market Revenue and Volume Forecast, by End Use
11.1.1. Biotechnology & Pharmaceutical Companies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Academic & Government Research Institutes
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Other end-users
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Products
12.1.2. Market Revenue and Volume Forecast, by Services
12.1.3. Market Revenue and Volume Forecast, by Application
12.1.4. Market Revenue and Volume Forecast, by End Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Products
12.1.5.2. Market Revenue and Volume Forecast, by Services
12.1.5.3. Market Revenue and Volume Forecast, by Application
12.1.5.4. Market Revenue and Volume Forecast, by End Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Products
12.1.6.2. Market Revenue and Volume Forecast, by Services
12.1.6.3. Market Revenue and Volume Forecast, by Application
12.1.6.4. Market Revenue and Volume Forecast, by End Use
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Products
12.2.2. Market Revenue and Volume Forecast, by Services
12.2.3. Market Revenue and Volume Forecast, by Application
12.2.4. Market Revenue and Volume Forecast, by End Use
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Products
12.2.5.2. Market Revenue and Volume Forecast, by Services
12.2.5.3. Market Revenue and Volume Forecast, by Application
12.2.5.4. Market Revenue and Volume Forecast, by End Use
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Products
12.2.6.2. Market Revenue and Volume Forecast, by Services
12.2.6.3. Market Revenue and Volume Forecast, by Application
12.2.6.4. Market Revenue and Volume Forecast, by End Use
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Products
12.2.7.2. Market Revenue and Volume Forecast, by Services
12.2.7.3. Market Revenue and Volume Forecast, by Application
12.2.7.4. Market Revenue and Volume Forecast, by End Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Products
12.2.8.2. Market Revenue and Volume Forecast, by Services
12.2.8.3. Market Revenue and Volume Forecast, by Application
12.2.8.4. Market Revenue and Volume Forecast, by End Use
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Products
12.3.2. Market Revenue and Volume Forecast, by Services
12.3.3. Market Revenue and Volume Forecast, by Application
12.3.4. Market Revenue and Volume Forecast, by End Use
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Products
12.3.5.2. Market Revenue and Volume Forecast, by Services
12.3.5.3. Market Revenue and Volume Forecast, by Application
12.3.5.4. Market Revenue and Volume Forecast, by End Use
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Products
12.3.6.2. Market Revenue and Volume Forecast, by Services
12.3.6.3. Market Revenue and Volume Forecast, by Application
12.3.6.4. Market Revenue and Volume Forecast, by End Use
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Products
12.3.7.2. Market Revenue and Volume Forecast, by Services
12.3.7.3. Market Revenue and Volume Forecast, by Application
12.3.7.4. Market Revenue and Volume Forecast, by End Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Products
12.3.8.2. Market Revenue and Volume Forecast, by Services
12.3.8.3. Market Revenue and Volume Forecast, by Application
12.3.8.4. Market Revenue and Volume Forecast, by End Use
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Products
12.4.2. Market Revenue and Volume Forecast, by Services
12.4.3. Market Revenue and Volume Forecast, by Application
12.4.4. Market Revenue and Volume Forecast, by End Use
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Products
12.4.5.2. Market Revenue and Volume Forecast, by Services
12.4.5.3. Market Revenue and Volume Forecast, by Application
12.4.5.4. Market Revenue and Volume Forecast, by End Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Products
12.4.6.2. Market Revenue and Volume Forecast, by Services
12.4.6.3. Market Revenue and Volume Forecast, by Application
12.4.6.4. Market Revenue and Volume Forecast, by End Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Products
12.4.7.2. Market Revenue and Volume Forecast, by Services
12.4.7.3. Market Revenue and Volume Forecast, by Application
12.4.7.4. Market Revenue and Volume Forecast, by End Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Products
12.4.8.2. Market Revenue and Volume Forecast, by Services
12.4.8.3. Market Revenue and Volume Forecast, by Application
12.4.8.4. Market Revenue and Volume Forecast, by End Use
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Products
12.5.2. Market Revenue and Volume Forecast, by Services
12.5.3. Market Revenue and Volume Forecast, by Application
12.5.4. Market Revenue and Volume Forecast, by End Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Products
12.5.5.2. Market Revenue and Volume Forecast, by Services
12.5.5.3. Market Revenue and Volume Forecast, by Application
12.5.5.4. Market Revenue and Volume Forecast, by End Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Products
12.5.6.2. Market Revenue and Volume Forecast, by Services
12.5.6.3. Market Revenue and Volume Forecast, by Application
12.5.6.4. Market Revenue and Volume Forecast, by End Use
13.1. Merck KGaA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. QIAGEN
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Thermo Fisher Scientific Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Synlogic
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GeneCopoeia, Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Horizon Discovery Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. New England Biolabs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Quantabio
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. NanoString
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. BioGenex
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of TermS
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample